DNA

Genetic research

Letermovir Proven Safe and Efficacious for Preventing CMV Reactivation in Pediatric Patients Undergoing HSCT

Pediatric patients undergoing hematopoietic stem cell transplant (HSCT) are at risk of developing cytomegalovirus (CMV) reactivation. A recent study published in the Transplantation and Cellular Therapy journal investigated the use of letermovir, a viral terminate inhibitor, for primary and secondary prophylaxis of CMV reactivation in pediatric patients. The study aimed